Institute of Hematology Oncology

Spain

Institute of Hematology Oncology

Spain
SEARCH FILTERS
Time filter
Source Type

Carreras E.,Institute of Hematology Oncology | Cahn J.Y.,Joseph Fourier University | Puozzo C.,IRPF | Kroger N.,University of Hamburg | And 4 more authors.
Anticancer Research | Year: 2010

This study investigated the effect of seizure prophylaxis on busulfan (Bu) plasma exposure. Twenty-four adult patients received an intravenous Bu-cyclophoshamide conditioning regimen prior to bone marrow transplantation. Busilvex® (0.8 mg/kg) was administered every six hours during four consecutive days. Clonazepam (0.025 to 0.03 mglkglday as a continuous 12-h i.v. infusion) was administered at least 12 hours prior to i.v. Bu dosing and continued until 24 hours after the last dose. Pharmacokinetic (PK) data were compared with those previously collected in patients (n=127) treated with phenytoin for seizure prophylaxis. Through population PK analysis, a 10% average increase (coeffiecient of variation, RSE=5.35%) in total clearance of Bu was quantified when Bu was associated with clonazepam as compared to phenytoin, which was considered as not being clinically relevant. The suspected induction on Bu metabolism by phenytoin should have resulted in the opposite effect. The patient efficacy and safety profiles were comparable between the two cohorts.


PubMed | Institute of Hematology Oncology
Type: Clinical Trial | Journal: Anticancer research | Year: 2010

This study investigated the effect of seizure prophylaxis on busulfan (Bu) plasma exposure. Twenty-four adult patients received an intravenous Bu-cyclophoshamide conditioning regimen prior to bone marrow transplantation. Busilvex (0.8 mg/kg) was administered every six hours during four consecutive days. Clonazepam (0.025 to 0.03 mg/kg/day as a continuous 12-h i.v. infusion) was administered at least 12 hours prior to i.v. Bu dosing and continued until 24 hours after the last dose. Pharmacokinetic (PK) data were compared with those previously collected in patients (n=127) treated with phenytoin for seizure prophylaxis. Through population PK analysis, a 10% average increase (coefficient of variation, RSE=5.35%) in total clearance of Bu was quantified when Bu was associated with clonazepam as compared to phenytoin, which was considered as not being clinically relevant. The suspected induction on Bu metabolism by phenytoin should have resulted in the opposite effect. The patient efficacy and safety profiles were comparable between the two cohorts.


PubMed | Institute of Hematology Oncology
Type: Journal Article | Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Year: 2016

5100 Background: 70% of cervical cancer patients in India are approximately 35 years old and present with stage IIIB disease. Current treatment modalities of concurrent chemo radiotherapy is improving survival in these patients but is also leading to permanent ovarian failure.Aim is to determine if Hormone Replacement Therapy (HRT) can relieve the symptoms and improve quality of life.A prospective controlled study was initiated from September 1997. 456 histologically proven squamous cell carcinoma cervix III B patients with age 35 years or less where included in the study. A detailed history of patient symptomatology was taken at the initiation of the therapy and after 6 weeks of completion of treatment. Since many symptoms of cancer and menopause are similar it was difficult to attribute it to a particular reason. Becks depression Inventory was used to access depression. All patients underwent counseling for HRT by the counsultant. 278 patients opted to take HRT. 0.625 mg of conjugated estrogen with 2.5mg medroxyprogesterone acetate continuously. Patients were evaluated at 6 weeks, 3 months and 1 year of HRT and results were compared to 178 patients who did not start HRT.After 6 weeks of completion of concurrent chemo radiotherapy treatment, 38.6% patients experienced hot flushes 33.8% suffered from night sweats and 30.4% had palpitations which were all increase from initial 8.3%,7.45% and 10.9% respectively. 62.6% patients had severe depression at the initiation of therapy which reduced to 54.9% on completion of therapy. At the end of one year the HRT group showed marked reduction in depression with only 4.67% patients being depressed compared to 30.3% patients in the non HRT users.This is statistically significant. (chi square) On follow up it was found that there was marked improvement in all symptoms in the HRT group as against the non HRT group.Hot flushes, night sweats, palpitations and depression are common after treatment for cancer cervix in younger patients.HRT plays a significant role in improving the quality of their life. No significant financial relationships to disclose.

Loading Institute of Hematology Oncology collaborators
Loading Institute of Hematology Oncology collaborators